Clinical Phase 1
Clinical Phase 1
The global market for prophylactic HPV vaccines is likely to grow rapidly as more and more countries expand national vaccination programmes to include HPV vaccinations for boys. In addition, it is now estimated that 60-70% of oropharyngeal cancers are caused by HPV virus infections, opening up a discussion on HPV vaccinations for adults.
More than 170 types of human papillomavirus have been fully sequenced and there are many more to be investigated. The most advanced approved HPV vaccine provides protection against 9 HPV types. In pre-clinical tests, 2A Pharma’s HPV vaccine candidate, formulated without adjuvant, has been shown to provide protection against more than 20 HPV types (and we are still testing), including several that can cause cancer and which existing vaccines do not protect against.
The HPV virus capsid consists of the L1 major protein and the L2 minor protein. The existing approved vaccines target the L1 protein, which varies significantly between HPV types. This means that different particles must be produced for each HPV type and then mixed in the final product, increasing production complexity cost.
The L2 capsid protein, targeted by 2A Pharma’s HPV vaccine, has portions that are well conserved across HPV types which means our vaccine provides protection for a broad range of HPV types with just one AAVLP particle type. The result is a superior product: broader protection and lower production cost.
2A Pharma’s AAVLP-HER2/Neu peptide vaccine candidate has in laboratory tests been shown to induce antibodies specific to human HER2. In mouse models, regression of breast cancer tumours was observed after vaccination. In a Proof of Concept study carried out at the Medical University of Vienna1, Austria, supported by Medigene AG, it was concluded that this vaccine strategy could help to establish active immunotherapy for breast-cancer patients.
2A Pharma’s B-cell epitope vaccine candidate, AAVLP-IgE, has in laboratory tests with non-human primates been shown to be effective at inducing anti-IgE antibodies. This gives the potential for a vaccine with similar benefits to approved anti‐human immunoglobulin E (IgE) antibody treatments of, for example, asthma.
2A Pharma’s anti-amyloid-beta vaccine candidate, AAVLP-Amyloid-β, has in laboratory tests with transgenic mice over expressing amyloid-beta mutant protein been shown to eliminate amyloid-beta soluble protein, clear plaque from the cortex and significantly reduce plaque from the hippocampus.
It is our hope that the drug candidate can be developed into a treatment for early stage Alzheimer’s disease.
2A Pharma’s anti-autoimmune vaccine candidate has potential in a number of indications. The vaccine is currently being tested in a vitiligo model in collaboration with a US academic partner.
A number of prophylactic HIV vaccines are in mid-stage clinical trials but published data indicates that vaccine candidates only provide around 50% protection against HIV infection. 2A Pharma is developing an alternative HIV vaccine which we believe will have superior characteristics. The vaccine candidate is initially being tested in collaboration with a European academic partner.
Head and neck cancers represents the sixth most common cancer worldwide, resulting in more than 350,000 deaths/year. Our AAVLP-HNC vaccine has the potential to minimize side effects, improve efficacy, and markedly reduce treatment costs. This will address an unmet medical need and benefit cancer patients as well as reduce healthcare expenses. In addition, our combination of advanced technologies will establish a versatile platform for developing further vaccines.